- References (1)
- Inventor Info
|Antigen/Gene or Protein Targets||BCAR3|
|Synonyms||Breast Cancer Anti-Estrogen Resistance 3; SH2 Domain-Containing Protein 3B; NSP2|
|Disease Keywords||Mammary ductal carcinoma, estrogen independent|
Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype.
Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in human breast cancer cells. This cell line is part of a panel of 16 cell lines (Cat No 154621-154635, 154642) which have been transfected with these genes, plus the parental (Cat No 154547).
This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
|Production Details||Full length BCAR3 cDNA was introduced in the estrogen-dependent ZR-75-1 cell line by transfection with lipofectamine|
|Research Area||Cancer, Drug Discovery & Development|
|Recommended Growing Conditions||RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17β-estradiol|
The cell line is resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells.
As a consequence of the presence of a BCAR genes, these cells can also proliferate in the absence of estrogen or even in the presence of anti-estrogens.
There are 1 reference entries for this reagent.View All References
No inventors are currently linked to this reagent.
Add an inventor
Add an inventor